Hepatic Encephalopathy
📧 Sign up to get email alerts when something new happens for Hepatic Encephalopathy.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-03-06Clinical Trial Update: The BRAINFOOD Trial to Prevent Recurrent Hepatic Encephalopathy. [NA]
A completed clinical trial (BRAINFOOD) investigating prevention of recurrent hepatic encephalopathy in patients with cirrhosis and ascites; …
-
FDA approval · 2024-02-20FDA Approved: LACTULOSE SOLUTION — Supplemental Application (Bajaj Medical, LLC)
FDA approved Bajaj Medical, LLC's supplemental application for Lactulose Solution USP (10 g/15 mL), confirming continued availability of the…
-
CLINICAL_TRIALS trial_result · 2024-01-09Clinical Trial Update: Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy [Phase 4]
Phase 4 trial update on rifaximin in subjects with severe hepatic impairment and hepatic encephalopathy; study terminated with posted result…
-
CLINICAL_TRIALS trial_result · 2023-10-17Clinical Trial Update: Efficacy of Lactoferrin as an Adjunct Therapy in Patients With Hepatic Encephalopathy [Phase 2]
Phase 2 clinical trial update evaluating lactoferrin as an adjunct therapy for hepatic encephalopathy.
-
CLINICAL_TRIALS trial_result · 2023-09-21Clinical Trial Update: Rifamycin in Minimal Hepatic Encephalopathy [Phase 2]
Phase 2 trial update for rifamycin in minimal hepatic encephalopathy has completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-07-13Clinical Trial Update: Efficacy of L-Ornithine L-Aspartate and Polyethylene Glycol in Cirrhotic Patients With Overt Hepatic Encephalopathy [Phase 4]
Phase 4 trial update investigating the efficacy of L-Ornithine L-Aspartate and polyethylene glycol in cirrhotic patients with overt hepatic …
-
CLINICAL_TRIALS trial_result · 2023-04-19Clinical Trial Update: Polyethylene Glycol Versus Lactulose on Hepatic Encephalopathy in Patients With Cirrhosis;(PEGHE Trial) [Phase 4]
Phase 4 trial comparing polyethylene glycol versus lactulose for hepatic encephalopathy in cirrhosis patients is ongoing with status unknown…
-
CLINICAL_TRIALS trial_result · 2023-04-13Clinical Trial Update: Allopurinol Versus Atorvastatin to Prevent Complications of Liver Cirrhosis [Phase 2, Phase 3]
A Phase 2/Phase 3 clinical trial comparing allopurinol to atorvastatin for preventing complications in liver cirrhosis and hepatic encephalo…
-
CLINICAL_TRIALS trial_result · 2023-04-05Clinical Trial Update: Effectiveness of Oral Lactulose Versus Lactulose Enema in Hepatic Encephalopathy [Phase 4]
Phase 4 trial update evaluating the effectiveness of oral lactulose versus lactulose enema in hepatic encephalopathy.
-
CLINICAL_TRIALS trial_result · 2022-06-10Clinical Trial Update: Fecal Transplant for Hepatic Encephalopathy [Phase 1, Phase 2]
Clinical trial update for fecal transplant in hepatic encephalopathy reporting completed phases 1 and 2.
-
CLINICAL_TRIALS trial_result · 2022-05-31Clinical Trial Update: HEAL STUDY (Hepatic Encephalopathy and Albumin Study) [Phase 2]
Phase 2 clinical trial update for HEAL STUDY investigating hepatic encephalopathy and albumin in cirrhosis; trial status completed.
-
CLINICAL_TRIALS trial_result · 2021-11-19Clinical Trial Update: Integrated Traditional Chinese and Clinical Medicine for Chronic Hepatitis B and Its Complication [Phase 3]
A Phase 3 clinical trial evaluating integrated traditional Chinese and clinical medicine for chronic hepatitis B and its complications is un…
-
CLINICAL_TRIALS trial_result · 2021-10-04Clinical Trial Update: Fecal Microbiota Transplantation (FMT) in the Management of Hepatic Encephalopathy (HE): a Pilot Study [Phase 1, Phase 2]
A pilot Phase 1/2 clinical trial evaluating fecal microbiota transplantation for hepatic encephalopathy has completed.
-
CLINICAL_TRIALS withdrawal · 2021-09-22Clinical Trial Update: MNK-6105 for Patients With Cirrhosis and High Ammonia Levels Affecting Brain Function [Phase 3]
A Phase 3 trial of MNK-6105 for hepatic encephalopathy in cirrhosis patients was withdrawn.
-
CLINICAL_TRIALS trial_result · 2021-09-16Clinical Trial Update: Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE) [Phase 2]
Phase 2B trial assessing efficacy and safety of Ornithine Phenylacetate in hospitalized patients with hepatic encephalopathy has completed, …
-
FDA approval · 2021-09-08FDA Approved: LACTULOSE — Supplemental Application (APOZEAL PHARMACEUTICALS INC)
FDA approved a supplemental application for Lactulose submitted by APOZEAL PHARMACEUTICALS INC, indicating an update to labeling and/or indi…
-
FDA approval · 2021-08-16FDA Approved: LACTULOSE — Supplemental Application (APOZEAL PHARMACEUTICALS INC)
FDA approved a supplemental application for Lactulose submitted by APOZEAL PHARMACEUTICALS INC, resulting in an approved labeling/indication…
-
CLINICAL_TRIALS trial_result · 2021-07-20Clinical Trial Update: MNK6106 for Liver Disease (Hepatic Cirrhosis) That in the Past Has Affected the Brain (Hepatic Encephalopathy) [Phase 2]
Phase 2 trial update for MNK6106 in hepatic cirrhosis with hepatic encephalopathy (HE) has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-05-10Clinical Trial Update: Efficacy of L-Ornithine L-Aspartate in Acute Hepatic Encephalopathy. [Phase 4]
Phase 4 trial update on the efficacy of L-Ornithine L-Aspartate for hepatic encephalopathy.
-
CLINICAL_TRIALS trial_result · 2021-02-03Clinical Trial Update: Microbial Resistance of Rifaximin in Hepatic Encephalopathy [Phase 4]
Phase 4 trial update on rifaximin for hepatic encephalopathy focusing on microbial resistance.
-
CLINICAL_TRIALS trial_result · 2020-12-17Clinical Trial Update: Rifaximin in Minimal Hepatic Encephalopathy [NA]
Clinical trial update for rifaximin in minimal hepatic encephalopathy has been completed with results posted.
-
CLINICAL_TRIALS trial_result · 2020-09-04Clinical Trial Update: Efficacy of Combined Oral L-ornithine-L-aspartate and Lactulose in Patients With Hepatic Encephalopathy [Phase 4]
Phase 4 trial update evaluating the efficacy of combined L-ornithine-L-aspartate with lactulose for hepatic encephalopathy.
-
FDA approval · 2020-03-24FDA Approved: LACTULOSE — Supplemental Application (PAI Holdings, LLC dba PAI Pharma)
The FDA approved a supplemental application for lactulose from PAI Holdings (PAI Pharma), updating its labeling and potentially expanding th…
-
CLINICAL_TRIALS trial_result · 2020-02-10Clinical Trial Update: A Retrospective, Open-label, Uncontrolled Cohort Study to Assess the Effectiveness and Safety of Lactulose Retention Enema in the Treatment of Cirrhotic Patients With Grade 3 or 4 (West Haven Criteria) Hepatic Encephalopathy (HE) [The RETRO Study]
A retrospective, open-label cohort study evaluating the effectiveness and safety of lactulose retention enema for treating hepatic encephalo…
-
CLINICAL_TRIALS trial_result · 2019-11-13Clinical Trial Update: Efficacy and Safety of Nitazoxanide in Preventing Recurrence of Hepatic Encephalopathy [Phase 3]
Phase 3 trial update on nitazoxanide for preventing recurrence of hepatic encephalopathy focusing on efficacy and safety.